摘要
目的探讨新辅助化疗治疗宫颈癌的临床疗效和预后影响因素。方法 98例宫颈癌患者术前进行新辅助化疗,3个疗程后进行根治性手术治疗,观察患者的肿瘤大小变化、临床疗效和预后相关因素。结果 98例患者中,完全缓解12例,部分缓解63例,总有效率为76.5%。所有患者治疗后肿瘤显著缩小,与治疗前差异有统计学意义(P<0.05)。影响新辅助化疗后宫颈癌患者的预后因素为临床分期、组织学分型、病理分级、肿瘤直径和淋巴结转移。结论新辅助化疗对早期宫颈癌患者具有显著优势,能够明显缩小瘤体,提高手术疗效,值得临床进一步推广。
Objective To investigate the clinical efficacy and prognosis factors of neoadjuvant chemotherapy in patients with cervical cancer. Methods A total of 98 patients with cervical cancer were treated with neoadjuvant chemotherapy, and performing radical surgery after three courses. Changes of tumor sizes, clinical efficacy and prognosis related factors were observed. Results The cases of complete response and partial response were 12 and 63, respectively, and total efficiency was 76. 5%. The post-therapy tumor sizes was significantly reduced compared with those of pre-therapy （ P 〈 0.05 ）. The affecting factors of prognosis in patients with cervical cancer after adjuvant chemotherapy were clinical stage, histological type, pathological grade, tumor size and lymph node metastasis. Conclusion Neoadjuvant chemotherapy not only has significant advantages for patients with early stage cervical cancer, but also can significantly reduce the tumor size and improve curative effect. It is worthy for further promotion.
出处
《中国肿瘤临床与康复》
2014年第8期971-973,共3页
Chinese Journal of Clinical Oncology and Rehabilitation
关键词
新辅助化疗
子宫肿瘤
治疗结果
预后
Neoadjuvant chemotherapy
Uterine neoplasms
Treatment outcome
Prognosis
